Raffaele Colombo, Director of Medicinal Chemistry at Zymeworks Inc., shared a post on X:
“From ASCO26: a Portuguese real-world study in patients with HER2-low breast cancer, adding to the growing body of literature on ‘ADC after ADC’ with similar payloads!
(Original data on the top, digitalized and re-plotted by patients on the bottom for better visualization!)”
Title: Sequence of similar-payload ADCs: Does it make sense in real-world HER2-low advanced breast cancer?—The Portuguese national study.
Author: Gonçalo Fernandes
Other articles featuring Dr. Colombo on OncoDaily.